TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Reports Private Market Data & Analytics Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Reports
Private Market Data & Analytics
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Companies / ArsenalBio Stock

ArsenalBio Stock

arsenalbio.comHealthcareFounded: 2019Funding to Date: $339.82MM

ArsenalBio is a biotechnology company looking to develop efficacious and safe cellular therapies for patients with chronic diseases and develops cellular drug discovery tools designed to provide medicines for cancer treatment. The company's tools operate in cell genome engineering and cell manufacturing platforms, enabling hospitals to create T-cell medicines for cancer treatment.

Buy or sell ArsenalBio stockLearn more about ArsenalBio IPO
Register for Details

For more details on financing and valuation for ArsenalBio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for ArsenalBio.

Register Today

ArsenalBio investors also invested in these private companies

Kleiner Perkins
Euclidean Capital
Westlake Village BioPartners
the Parker Institute

Team

Management Team

Tarjei Mikkelsen
Chief Technology Officer
Kenneth Drazan MD
Co-Founder, Director, Chief Executive Officer, President and Board Member
Jane Grogan
Chief Scientific Officer

Board Members

Sean Parker
Parker Institute for Cancer Immunotherapy
Alexander Marson Ph.D
Brook Byers Ph.D
Kleiner Perkins
Beth Seidenberg MD
Westlake Village BioPartners

Other companies like ArsenalBio in the Healthcare sector

Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.67B
Acelyrin
Sector
Healthcare
Last Round Est. Valuation
$809.52MM
Colossal Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.01B
Paradromics
Sector
Healthcare
 
 
Grail
Sector
Healthcare
Last Round Est. Valuation
$4.26B
OURA
Sector
Healthcare
 
 
Artera
Sector
Healthcare
Last Round Est. Valuation
$396.01MM
Synchron
Sector
Healthcare
Last Round Est. Valuation
$400.53MM
Alzheon
Sector
Healthcare
Last Round Est. Valuation
$1.53B

News

Crunchbase 09/08/2022
ArsenalBio Raises $220M As Cell Therapy’s Popularity Grows
As innovations in cell therapy continue to grow, San Francisco-based ArsenalBio this week announced it raised a whopping $220 million in Series B funding, one of the largest rounds this year for a cell therapy venture.
TechCrunch 10/17/2019
ArsenalBio emerges from stealth with $85 million and a dream team to fight cancer – TechCrunch
The story behind ArsenalBio begins with Sean Parker’s Institute for Cancer Immunotherapy. Founded in 2016, the Institute has been instrumental in providing a space for the top researchers into cancer across different fields to collaborate and communicate on the latest breakthroughs in setting…
FinSMEs 10/17/2019
ArsenalBio Raises $85M in Series A Financing | FinSMEs
ArsenalBio, a South San Francisco, Calif.-based programmable cell therapy company, raised $85m in Series A financing round

Trending Companies

Frequently Asked Questions

Updated on: Jun 3, 2023